Laekna, Inc.

Research Laekna, Inc. (2105.HK) on Bullrun: market cap HKD 2.98B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker2105.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 2.98B
Financial periodFY2025
RevenueCNY 106.72M
Net income-CNY 229.32M
Free cash flow-CNY 93.88M
Gross margin81.0%

Valuation Snapshot

latest market cap is HKD 2.98B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 106.72M	-CNY 229.32M	-CNY 93.88M	81.0%	-0.59	CNY 1.24B	CNY 120.84M	CNY 1.18B
FY2024	CNY 0	-CNY 254.30M	-CNY 280.22M	n/a	-0.71	CNY 636.42M	CNY 104.33M	CNY 804.79M
FY2023	CNY 0	-CNY 368.81M	-CNY 296.92M	n/a	-1.68	CNY 440.82M	CNY 56.39M	CNY 803.97M
FY2022	CNY 0	-CNY 781.59M	-CNY 311.37M	n/a	-20.04	CNY 323.07M	CNY 28.30M	-CNY 1.91B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 2.98B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Laekna, Inc.

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is Laekna, Inc.'s market cap?

Laekna, Inc.'s market capitalization is HKD 2.98B.

What does Laekna, Inc. do?

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide.